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In its widely quoted report, the Commission on Health Research for Development drew attention to
the importance of health research as the essential link to equity in development 1. It proposed that
developing countries should review and strengthen the management of health research so as to meet
their national needs as well as contribute to the global fund of knowledge. The Commission also
recommended that governments in developing countries should allocate at least 2% of the national
health budget for research and that 5% of the budget for large externally funded programmes should
be assigned to research and capacity strengthening. The Commission hoped that these financial
arrangements would provide a secure foundation for funding the priority research needs in
developing countries, based on the new concept of Essential National Health Research 2. The
expectation was that developing countries would review their current spending on health research
and would strive to meet the stated goals.
Rather disappointingly, neither the developing world nor the donor community enthusiastically
followed up the Commission's recommendations, although there were a few exceptions. Further-
more, since most developing countries were not actively tracking the pattern of spending on health
research, it was difficult to know how close they were to the target and what trends were occurring
over time. One major obstacle was the lack of tested methodologies for monitoring spending on
health research at the country level. This report attempts to fill this gap. The Global Forum for Health
Research has tackled the problem through its support of a network of investigators. This document
contains a preliminary report of their findings. The aim of the publication is to stimulate interest in
this important issue in the hope that other investigators will critically review the methodology that
this team has developed and perhaps offer refinements. Furthermore, the tentative results from a few
countries should stimulate others to follow the example and provide data from many more countries.
Ideally, other studies will adopt the core definitions so as to facilitate comparisons among countries
and also to examine trends over time.
The results of this initial study were broadly predictable in that there is still a wide gap between the
recommendations of the Commission and the pattern of spending on health research in many
developing countries. The more advanced developing countries are making more generous alloca-
tions but more needs to be done especially in the least developed countries. Inadequate allocation of
national resources for health research makes scientists so heavily dependent on foreign grants that
they tend to ignore national priorities in favour of lucrative contracts from foreign sponsors. The
monitoring of resource flows will provide scientists and other stakeholders with a powerful tool for
advocacy in persuading national governments and foreign donors to support priority health research.
Foreword by 
by Adetokunbo O. Lucas, MD
Chair, Foundation Council, Global Forum for Health Research
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Task Force on Health Research for Development, 1991. Essential National Health Research. A Strategy for Action in Health and Human Development,
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resource flows at both the global and national
levels. Furthermore, the situation is evolving.
For example, with the demographic and
epidemiological transitions experienced in
developing countries, these countries are bound
to benefit more from the research findings
undertaken in more advanced countries.
However, transmission of findings from the
more advanced countries to the developing
world is not straightforward in view of the
following factors: (a) communicable diseases
not prevalent in the more advanced countries
still represent a large share of disease burden in
developing countries; (b) the determinants of
ill-health can vary greatly between regions; (c)
the level of development and performance of
health systems vary greatly between countries;
(d) access to effective treatment, medicines and
other research results particularly for the poorer
segments of the population are very different
between and within countries; (e) interventions
for non-communicable diseases available in
advanced countries may not be directly adapt-
able to developing countries or appropriate due
to cost and infrastructure requirements, and may
not be the most cost-effective intervention in the
context of developing countries, particularly for
the poorer segments of the population.  
In view of this, the gap remains enormous and
the need to correct it is just as urgent. In order to
ensure that the large reservoir of knowledge
available in more advanced countries can be
transformed into actual gains of healthy life
years in developing countries, it is necessary to
increase research particularly in the following
areas (as proposed, amongst others, by the 1996
report of the Ad Hoc Committee on Health
Research and The 10/90 Report on Health
1. Introduction 
Health research is essential to the design and
implementation of health interventions, health
policies and health service delivery. Financing
health research and development (R&D) is
critical to its success. 
The information on health research financing is
fragmented. This study aims to provide decision-
makers with an overview of currently available
information on resource flows into health
research. In this rapidly changing environment
of funding flows into health research, it is
critical to have access to information and to
analyse it on an ongoing basis. 
The main feature of the study is less to provide
an overall figure (broadly estimated at close to
US$73.5 billion for 1998 from the public and
private sectors combined) than to describe the
process for arriving at these estimates as a basis
for further improvements, and to indicate what
to expect from the various data sources and
research approaches. In addition, this study
presents information on health research funding
by developing countries not available before. 
2. Overview of the context 
For the past decade, and since the ground-
breaking work of the Commission on Health
Research and Development in 1990, the
disequilibrium in health research has been
captured in the expression “the 10/90 gap” to
indicate the huge discrepancy between the
magnitude of disease burden in the world and
the allocation of research funding. The exact
figures are not known. This will require a lot
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US$56 billion in 1992 (in current terms). It is
estimated that up to one third of this increase is
in real terms. In the course of this study, it
became evident that important changes were
taking place in the health donor community
with implications for health research in, and
relevant to, developing countries. Public
funding (47% of the total funding into health
research) grew in the advanced countries as a
group and in virtually all the individual
countries. Insert ES.2 gives an overview of the
public investments into health research for the
countries investing the most into health research
and the evolution of their investments between
1986 and 1998. 
Investments by the private pharmaceutical
industry accounted for about 42% of total
investments into health research worldwide.
Information on the cost of research and clinical
trials for discovery and development of medi-
cines was not attempted in this study. The
widely quoted figure of US$500 million re-
quired to develop a new drug was not evaluated
in this study. 
The present study reports information on data
from developing countries and countries in
transition not available earlier. The study did not
attempt to do a comprehensive review of all
developing countries investing into health
research. It focused on a few selected countries
Research 2000 published by the Global Forum
for Health Research):
• Analysis of the burden of disease at the coun-
try and global levels.
• Analysis of the determinants of health, taking
into account not only the biomedical sector
but (i) behavioural factors affecting health at
the individual and community levels, (ii)
factors in sectors other than health having a
large impact on people's health, and (iii)
factors at the macro-economic policy level.
• Analysis of the current knowledge and of the
cost-effectiveness of present interventions to
compare viable options at the country and
global levels.
• Analysis of the potential cost-effectiveness of
future interventions at the country and global
levels.
• Analysis of resource flows into health research
at the country and global levels.
This is the context in which the present study is
situated. Its aim is to contribute to the last of the
steps mentioned above.
3. Overview of the present study 
This study is the result of teamwork. Members
of an Advisory Group, acting in their individual
capacity, debated and informed the process for
three years. The study presents a new
classification system for
R&D information, which
results from evaluating past
achievements. It proposes a
future strategy to continue to
track health research finan-
cing with the involvement of
a larger number of partners. 
Total worldwide investments
into health research was
calculated at close to
US$73.5 billion for 1998 by
both the public and the
private sectors (Insert ES.1)








Public funding: advanced and transition countries 34.5 47
Private funding: pharmaceutical industry 30.5 42
Private not-for-profit funding 6.0 8
Public funding: developing countries 2.5 3
Total 73.5 100
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was not included in this study but will be
included in the second phase. Most other devel-
oping countries and countries in transition
studied invested less than 1% of their national
health expenditures into health research. Econ-
omic hardship generally results in lower
national investments into health research.
Private foundations and other not-for-profit
organizations accounted for an estimated 8% of
the total health research funding. The numbers
and funding of private sponsors of research
increased in the late 1990s.
This study proposes a classification method
pilot-tested during the course of this study
which can be used to incorporate information
from developing countries, countries in tran-
sition and advanced countries. The system
attempts to capture also investments into
research capacity building and health systems,
two areas frequently left outside of the
calculations. The study illustrates the practical
use of the classification system by collecting
information from national and international
sources. The classification of resource flows
into health research is presented in insert ES.3.
Information derived from this framework can be
used by policy-makers at the national, regional
and global levels. This information can be used
to relate health research priorities with funding
from both the national or international sources.
While funding has increased somewhat in the
1990s as reported, the problem of allocation
remains practically the same as in 1990.
Research is still seen as a luxury in developing
countries and the results of research not very
relevant to define policies. Investments in health
research need to focus on determinants and
diseases corresponding to the heaviest burden
and to take a long-term perspective. It is also
important to invest in research capacity building
in the South and to ensure the survival of
research institutions that have been struggling to
survive over the years. Moreover, the large majority
of health research funding is invested into
in which teams conducted special surveys on
health R&D information or on countries for
which published information existed. The Com-
mission on Health Research for Development in
its 1990 report recommended that at least 2% of
total national health expenditures in less devel-
oped countries be allocated to health research
and capacity building. This recommendation
may be based on the fact that most advanced
countries spend the equivalent of 1% to 2% of
their national health expenditures on health
research. While none of the developing coun-
tries studied matched the 2% figure recom-
mended by the Commission, Brazil and Cuba
were close to that level of investment in 1998.
For lack of data available to the study




Trends in public health R&D funding
1986 to 1998 in advanced countries
Million US$ at 1995 prices and




1 See details in Chapter 3.
Source: Eurostat (annual), OECD (annual) and national
publications.
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biomedical research with little investment into
health economics and social sciences. Finally, it
is necessary to ensure that the outputs of
research are implemented in health and
development programmes and transformed into
measurable health improvements for the people. 
Gathering, interpreting and using information of
resource flows into health research is one of the
crucial steps to identify and understand health
research priorities at the national, regional and
global levels. Only by measuring efforts, both
human and financial, invested into research of
the most neglected health problems in the
world, will we know how much priority these
are given. This study is a step in that direction
and a basis for a next round of studies in this
critical area. We hope that this study will inspire




Classification of resource flows for
health research
Levels of aggregation of R&D funds                
A1. Non-oriented, fundamental research
A2. Health conditions, diseases or injuries 
(classified by disease)
A3. Exposures, risk factors that impact on 
health (determinants)
A4. Health systems research
A5. Research capacity building
Further details on the classification and subcategories can be
found in Annex 2.
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